FDA approves Bravecto Quantum, the first injectable flea and tick treatment offering dogs up to 12 months of protection.

Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study. AbbVie is conducting a Phase 3 clinical study ...

The FDA has granted accelerated approval to Datroway for adults with previously-treated, locally advanced or metastatic EGFR-mutated NSCLC.

In 2024, scientists stumbled upon a potential new treatment for hereditary-patterned baldness, the most common cause of hair ...

Popular hair loss supplements like Nutrafol and biotin and prescriptions like finasteride have come under fire for potential ...

The first pill to treat adults with severe alopecia was approved by the U.S. Food and Drug Administration on Monday. Olumiant (baricitinib) is the first FDA-approved alopecia therapy that treats the ...

June brought major blood cancer updates, and CURE is sharing the latest in myelofibrosis treatment and FDA breakthroughs, as ...

Matthew Riccardi was just 11 years old when he was diagnosed with the same condition: alopecia areata, an autoimmune disorder that targets hair follicles. Much like Campbell, the then-sixth grader ...

The U.S. Food and Drug Administration's approval of lenacapavir, a twice-a-year injectable medication that has been shown to prevent HIV infections leaves questions of access and cost largely ...

Dato-DXd was granted accelerated approval for use in adults with EGFR-mutated NSCLC after EGFR-targeted therapy and platinum-based chemotherapy.

Revuforj is an oral, first-in-class menin inhibitor that was FDA approved in 2024 for the treatment of R/R acute leukemia with a KMT2A translocation in adult and pediatric patients one year and older.